371 related articles for article (PubMed ID: 27503089)
1. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
[TBL] [Abstract][Full Text] [Related]
2. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
3. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition.
Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ
J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453
[TBL] [Abstract][Full Text] [Related]
5. Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients.
Fernández B; Lara Ordóñez AJ; Fdez E; Mutez E; Comptdaer T; Leghay C; Kreisler A; Simonin C; Vandewynckel L; Defebvre L; Destée A; Bleuse S; Taymans JM; Chartier-Harlin MC; Hilfiker S
Biochem J; 2019 Oct; 476(19):2797-2813. PubMed ID: 31527116
[TBL] [Abstract][Full Text] [Related]
6. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
[TBL] [Abstract][Full Text] [Related]
7. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.
Dzamko N; Inesta-Vaquera F; Zhang J; Xie C; Cai H; Arthur S; Tan L; Choi H; Gray N; Cohen P; Pedrioli P; Clark K; Alessi DR
PLoS One; 2012; 7(6):e39132. PubMed ID: 22723946
[TBL] [Abstract][Full Text] [Related]
8. Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.
Thirstrup K; Dächsel JC; Oppermann FS; Williamson DS; Smith GP; Fog K; Christensen KV
Sci Rep; 2017 Aug; 7(1):10300. PubMed ID: 28860483
[TBL] [Abstract][Full Text] [Related]
9. An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.
Padmanabhan S; Lanz TA; Gorman D; Wolfe M; Joyce A; Cabrera C; Lawrence-Henderson R; Levers N; Joshi N; Ma TC; Liong C; Narayan S; Alcalay RN; Hutten SJ; Baptista MAS; Merchant K
J Parkinsons Dis; 2020; 10(2):623-629. PubMed ID: 32007961
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization.
Dzamko N; Deak M; Hentati F; Reith AD; Prescott AR; Alessi DR; Nichols RJ
Biochem J; 2010 Sep; 430(3):405-13. PubMed ID: 20659021
[TBL] [Abstract][Full Text] [Related]
11. Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites.
Nirujogi RS; Tonelli F; Taylor M; Lis P; Zimprich A; Sammler E; Alessi DR
Biochem J; 2021 Jan; 478(2):299-326. PubMed ID: 33367571
[TBL] [Abstract][Full Text] [Related]
12. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM
Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255
[TBL] [Abstract][Full Text] [Related]
13. LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?
Taymans JM; Mutez E; Drouyer M; Sibran W; Chartier-Harlin MC
Biochem Soc Trans; 2017 Feb; 45(1):207-212. PubMed ID: 28202674
[TBL] [Abstract][Full Text] [Related]
14. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
[TBL] [Abstract][Full Text] [Related]
15. Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation.
Hermanson SB; Carlson CB; Riddle SM; Zhao J; Vogel KW; Nichols RJ; Bi K
PLoS One; 2012; 7(8):e43580. PubMed ID: 22952710
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between the kinase activity of LRRK2 harboring kinase-modifying mutations and its phosphorylation at Ser910, 935, and Ser955.
Ito G; Fujimoto T; Kamikawaji S; Kuwahara T; Iwatsubo T
PLoS One; 2014; 9(5):e97988. PubMed ID: 24836358
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson's disease.
Gonzalez-Hunt CP; Thacker EA; Toste CM; Boularand S; Deprets S; Dubois L; Sanders LH
Sci Rep; 2020 Oct; 10(1):17293. PubMed ID: 33057100
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Biomarkers of Sporadic Parkinson's Disease and LRRK2 Kinase Inhibition.
Smith GA; Jansson J; Rocha EM; Osborn T; Hallett PJ; Isacson O
Mol Neurobiol; 2016 Oct; 53(8):5161-77. PubMed ID: 26399642
[TBL] [Abstract][Full Text] [Related]
19. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.
Jennings D; Huntwork-Rodriguez S; Vissers MFJM; Daryani VM; Diaz D; Goo MS; Chen JJ; Maciuca R; Fraser K; Mabrouk OS; van de Wetering de Rooij J; Heuberger JAAC; Groeneveld GJ; Borin MT; Cruz-Herranz A; Graham D; Scearce-Levie K; De Vicente J; Henry AG; Chin P; Ho C; Troyer MD
Mov Disord; 2023 Mar; 38(3):386-398. PubMed ID: 36807624
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.
Deng X; Dzamko N; Prescott A; Davies P; Liu Q; Yang Q; Lee JD; Patricelli MP; Nomanbhoy TK; Alessi DR; Gray NS
Nat Chem Biol; 2011 Apr; 7(4):203-5. PubMed ID: 21378983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
